Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.49 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14204990 | 0.87 | SETDB1 (0.59) | MTNR1ASETDB1HPGDNPSR1MTNR1B | |
| SCHEMBL9635048 | 0.86 | ALDH1A1 (0.47) | GABRA1GABRB2HPGDHTTCYP2D6 | |
| SCHEMBL10125651 | 0.83 | HPGD (0.66) | GABRA1GABRB2HPGDHTTNPC1 | |
| SCHEMBL13154935 | 0.81 | HTT (0.46) | GABRA1GABRB2HPGDHTTNPSR1 | |
| SCHEMBL14651452 | 0.81 | SETDB1 (0.54) | MTNR1ASETDB1HPGDHTTNPSR1 | |
| SCHEMBL29675775 | 0.79 | SETDB1 (0.53) | MTNR1ASETDB1HPGDNPSR1MTNR1B | |
| SCHEMBL22803243 | 0.79 | HPGD (0.48) | GABRA1GABRB2HPGDHTTNPC1 | |
| Bicarbonate SCHEMBL27568192 | 0.78 | GABRA1 (0.58) | GABRA1GABRB2NPC1 | |
| SCHEMBL10781973 | 0.78 | SETDB1 (0.51) | MTNR1ASETDB1HPGDNPSR1MTNR1B | |
| SCHEMBL17123628 | 0.78 | SETDB1 (0.51) | MTNR1ASETDB1HPGDNPSR1MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-23 | — | — | US | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | MTNR1A 2567/4885SETDB1 1463/4885GABRA1 4045/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | MTNR1A 2382/4885SETDB1 625/4885GABRA1 4794/4885 |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | MTNR1A 2897/4885SETDB1 182/4885GABRA1 4596/4885 |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | MTNR1A 2567/4885SETDB1 1463/4885GABRA1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.